ISSUE 1521
| The full article is available to subscribers | Subscriber Login |
The FDA has approved the selective alpha1A-adrenergic receptor agonist oxymetazoline as a 1% cream (Rhofade – Allergan) for topical treatment of persistent facial erythema of rosacea in adults. Brimonidine, a selective alpha2-adrenergic receptor agonist, was approved in 2013 as a 0.33% gel (Mirvaso) for the same indication.1 Like Mirvaso, Rhofade is not indicated for treatment of inflammatory lesions of rosacea. Oxymetazoline has been available over the counter for many years as a nasal decongestant spray (Afrin, and others).
TREATMENT OF ROSACEA — Rosacea is a common, chronic inflammatory facial condition of unknown cause characterized by erythema, telangiectasia, and/or acneiform lesions (papules and pustules), usually on the central part of the face. Avoidance of exposure to extremes of temperature, hot baths
... more- Brimonidine gel (Mirvaso) for rosacea. Med Lett Drugs Ther 2013; 55:82.
- National Rosacea Society. Rosacea triggers survey. Available at: www.rosacea.org. Accessed May 11, 2017.
- S Li et al. Alcohol intake and risk of rosacea in US women. J Am Acad Dermatol 2017 April 1 (epub).
- Rosacea treatment update: recommendations from the Global Rosacea Consensus (ROSCO) panel. Br J Dermatol 2017; 176:465.
- Drugs for rosacea. Med Lett Drugs Ther 2016; 58:16.
- Y Asai et al. Canadian clinical practice guidelines for rosacea. J Cutan Med Surg 2016; 20:432.
- LK Oge' et al. Rosacea: diagnosis and treatment. Am Fam Physician 2015; 92:187.
- EJ van Zuuren et al. Interventions for rosacea. Cochrane Database Syst Rev 2015 April 28; (4):CD003262.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Immediate Online access to current issue and archives from 1988 to the present
- Mobile access to our mobile site and free apps for iOS, Android and Kindle
- FREE online per issue CME/CE
Article code: 1521c
Electronic, downloadable article - $25
